Correlation of Major Cytogenetic Response with a Pharmacogenetic Marker in Chronic Myeloid Leukemia Patients Treated with Imatinib (STI571)

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2265-2271

  Dressman, Marlene A ^a,b   Malinowski, Rachel ^a   McLean, Lee Anne ^a   Gathmann, Insa ^a   Capdeville, Renaud ^a   Hensley, Martee ^a   Polymeropoulos, Mihael H ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Vanda Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACOGENETICS; PHILADELPHIA 1 CHROMOSOME; POLYMORPHIC LOCUS; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 15; DISEASE PROGRESSION; GENOTYPE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LOGISTIC MODELS; MODELS, GENETIC; MULTIVARIATE ANALYSIS; PHENOTYPE; PIPERAZINES; POLYMORPHISM, GENETIC; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 1842426649     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0785-3     Document Type: Article

References (12)

1. Druker BJ, O'Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2002;111-35 Review.
2. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
4. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
5. Lee SJ, Anasetti C, Horowitz MM, Antin JH. Initial therapy for chronic myelogenous leukemia: playing the odds. J Clin Oncol 1998;16:2897-903.
6. O'Brien SG, Guilhot F, Larson RA, et al. Imatanib compared with interferon and low-dose cytarbine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
7. Kaneta Y, Kagami Y, Katagiri T, et al. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res 2002;93:849-56.
8. McLean L, Gathmann I, Capdeville R, et al. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin. Cancer Res 2004;10:155-65.
9. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis myeloid leukemia. Cancer Cell 2002;2:117-25.
10. Lyamichev V, Mast AL, Hall JG, et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol 1999;17:292-6.
11. Hasford J, Pfirrmann M, Hehlmann R, et al. New prognostic score for survival of patients with chronic myeloid leukemia treated with interferon α. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst (Bethesda) 1998;90:850-8.
12. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.